NCT06066359View on ClinicalTrials.gov

Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

November 30, 2023

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2028

Conditions
Myeloma
Interventions
DRUG

Fludarabine phosphate

Given by (IV) vein

DRUG

Cyclophosphamide

Given by (IV) vein

DRUG

NY-ESO-1 TCR/IL-15 NK

Given by (IV) vein

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER